Concepta PLC Appointment China Country Manager
December 08 2016 - 1:00AM
RNS Non-Regulatory
TIDMCPT
Concepta PLC
08 December 2016
8 December 2016
Concepta plc ("Concepta" or "the Company")
Appointment of China Country Manager Ahead of myLotus Fertility
Product Launch
Concepta plc (AIM:CPT), the UK healthcare company targeting the
personalised mobile health market with a primary focus on women's
fertility, is pleased to announce that it has appointed Kevin Su
Wei as its China Country Manager, based in Shanghai, with immediate
effect. This appointment is in line with the Company's strategy of
launching its myLotus product, targeted at women with unexplained
infertility* into its first international market, China, early
2017.
Mr Su Wei has over 10 years' sales, distribution and opinion
leader management experience in healthcare and specifically women's
health. He has held management positions at Merck Millipore, the
life sciences division of global healthcare player Millipore
corporation and at Inverness Medical (now Alere), a leading
innovative global diagnostics company.
At Concepta Kevin will build Concepta's distributor network and
lead the set up of Concepta's Chinese subsidiary in line with the
Company's growth projections. Kevin's past experience in China and
with fertility products ideally positions him to build Concepta's
brand and product presence in China.
Erik Henau, CEO of Concepta says: "We are delighted to welcome
Kevin as part of our Chinese division here at Concepta. He brings
with him a wealth of experience both in healthcare and specifically
the women's healthcare market in China that will be invaluable to
Concepta as we look to launch our myLotus fertility product in the
country early 2017. We look forward to updating the market in due
course on the myLotus launch into China and our on-going
developments in the UK and Europe as we target the product launch
into our second international market towards the end of 2017."
ENDS
Enquiries:
The Company
Adam Reynolds, Chairman
Tel: +44 (0) 7785 908158
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin/Mark Brady
Tel: +44 (0)20 368 3550
Beaufort Securities Limited (Broker)
Jon Belliss
Tel: +44 (0)20 7382 8300
Yellow Jersey PR Limited (Financial PR)
Felicity Winkles/ Joe Burgess
Tel: +44 (0) 7748 843 871
About Concepta Plc:
Concepta plc is a pioneering UK healthcare company that has
developed a proprietary platform and products targeted at the
personalised mobile health market with a primary focus on women's
fertility and specifically unexplained infertility*.
Founded in 2013, Concepta has developed a revolutionary flagship
product 'myLotus' for home self-testing that helps women with
unexplained infertility to conceive.
myLotus is the only consumer product which allows both
quantitative and qualitative measurements of measurement of a
woman's personal hCG and LH hormone levels in an easy to use home
test to facilitate higher conception rates and early diagnosis of
any fertility problems. Competitor products currently only allow
qualitative measurement and are based on the 'average woman'.
Concepta has a defined route to market for its new 'my Lotus'
product with Regulatory approvals for launch in China in place for
2016 and CE-Marking for UK and Europe to follow in 2017 where the
revenue potential of the Chinese and EU infertility market is worth
c.GBP600m per annum for the company.
*Unexplained infertility refers to women that have been unable
to conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQVLBBQLFXFBX
(END) Dow Jones Newswires
December 08, 2016 02:00 ET (07:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024